Dr. Strosberg’s interests center on development and implementation of biomarker-driven therapeutics into patient-based therapeutic trials. Collaborative research led to the identification of new molecular prognostic markers (including palladin and RUNX1T1) associated with malignant progression of pancreatic neuroendocrine tumors. His data on treatment of metastatic pancreatic endocrine carcinomas with the novel combination of capecitabine and temozolomide was recognized internationally. Dr. Strosberg and colleagues are analyzing whether deficiency of the O6 Methylguanine DNA Methyltransferase (MGMT) enzyme is predictive for response. He also completed a phase II study of hepatic artery embolization followed by sunitinib, a VEGF-receptor inhibitor. Initial analysis showed that embolization causes a surge in serum VEGF which can potentially lead to rapid angiogenesis after embolization. He developed a multicenter phase II study of an IGF-receptor inhibitor for treatment of carcinoid and pancreatic neuroendocrine tumors to analyze whether upregulation of the IGF-R pathway predicts for response. He also developed two investigator-initiated clinical trials of targeted therapy for metastatic colorectal cancer, including a phase IIB multicenter, randomized, placebo-controlled trial of a novel IGF-receptor inhibitor and a phase II NCI-supported study of a RO4929097, a gamma-secretase inhibitor. Both trials incorporate predictive serum and immunohistochemical biomarkers pertaining to the Notch and insulin-like growth factor pathways.